Search Results 161-170 of 23011 for Phase

1. A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies - Mayo Clinic

   A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies · Overview · Participation eligibility.

2. Phase 2 Nab®-Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects with Locally Advanced Pancreatic Cancer (LAPC) - Mayo Clinic

   This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their ...

3. A Phase 1B/​2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies (ARTACUS) - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

4. SUPRAME-ACTengine® IMA203 Vs. Investigator's Choice Of Treatment In Previously Treated, Unresectable Or Metastatic Cutaneous Melanoma - Mayo Clinic

   Study phase. 3. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase ...

5. A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma - Mayo Clinic

   The purpose of this study is to determine the overall survival of patients treated with Vigil versus gemcitabine/docetaxel. Participation eligibility.

6. Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 - Mayo Clinic

   This is a Phase 1b, open label, multi-center study of CMB305 (sequentially administered LV305 [a dendritic cell-targeting viral vector expressing the NY-ESO-1 ...

7. A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

8. A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease - Mayo Clinic

   A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease · Overview · Participation eligibility · Participating Mayo ...

9. A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - Mayo Clinic

   A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · Overview.

10. Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/​Refractory T-cell Non-Hodgkin Lymphoma - Mayo Clinic

    About this study. The purpose of this study is to evaluate a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).